WASHINGTON, DC (August. 3, 2017) – The Association for Accessible Medicines (AAM) and it’s Biosimilars Council applauds the leadership of Senator Lamar Alexander (R-TN) Sen. Patty Murray (D-WA), Sen. Susan Collins (R-ME), Sen. Claire McCaskill (D-MO) and Sen. Al Franken (D-MN), and thanks the United States Senate for overwhelmingly passing the FDA Reauthorization Act of 2017 (FDARA) by a vote of 94-1.
“As the country grapples with the high price of health care, the strong bipartisan vote in the Senate recognizes the most effective and efficient way to contain prescription drug costs is to enhance competition by increasing the number of generic and biosimilar medicines available to patients,” stated Chester “Chip” Davis, Jr., President and CEO.
The GDUFA II and BsUFA II agreements will put in place the framework for using the best processes and science available to approve new safe, effective and affordable generic and biosimilar medicines. AAM and our members look forward to the President swiftly signing FDARA; working with the FDA to increase the number of applications reviewed and approved; and to ensuring a sustainable and competitive market for generics and biosimilars that will serve the best interests of patients moving forward.